Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations | MicrobiomeTrials← Back to trialsNCT01861106
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2013-07-24Est. Completion: 2027-12-31
Enrollment target: 144 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Chronic Myelomonocytic LeukemiaChronic Myelomonocytic Leukemia-1Chronic Myelomonocytic Leukemia-2Myelodysplastic SyndromeMyelodysplastic Syndrome With Excess BlastsMyelodysplastic Syndrome With Excess Blasts-1Myelodysplastic Syndrome/Acute Myeloid Leukemia
This randomized phase II/III trial studies how well azacitidine works with or without lenalidomide or vorinostat in trea…
Birmingham, United StatesEst. completion Jun 1, 2015
DOCK8
GATA2 Deficancy
Background:
\- Gene therapy is being investigated as a possible treatment for individuals with immunodeficiency disease…